skip to main content

    Updated Visitor Guidelines

 

MENU

 

Report: Adjuvant capecitabine therapy can improve outcomes in biliary tract cancer

Date Visible: 
05/22/2017 - 3:45pm

Media contact: Jessica Webster Sendra, 734-764-2220 |  Patients may contact Cancer AnswerLine, 800-865-1125

In a randomized clinical trial conducted by researchers at University of Southampton, biliary cancer patients treated with capecitabine as adjuvant therapy lived, on average, more than a year longer than those who were only observed, according to a post in HemOnc Today. 

The research will be presented at the ASCO annual meeting in June. 

“This study helps resolve long-standing questions about adjuvant treatment for biliary tract cancer, for which there has been no standard of care,” says ASCO president Daniel Hayes, M.D., professor of internal medicine, and clinical director of the Breast Oncology Program at the University of Michigan Rogel Cancer Center. “This oral chemotherapy is widely available and can offer patients the chance to live more than a year longer.